CagriSema combines cagrilintide, an amylin analogue, with semaglutide, a GLP-1 receptor agonist. The combination is designed around complementary metabolic pathways. That mechanism explains the research rationale; the clinical evidence and regulatory status require their own examination.
Application does not mean approval
Novo Nordisk announced a US marketing application on 18 December 2025 for the investigational once-weekly injectable combination. That was a sponsor announcement about submission, not an FDA approval. The sources reviewed for this profile do not verify subsequent US approval or EU marketing authorisation. The sponsor still describes it as investigational on 30 September 2026. We retain that development status and explicitly mark jurisdictional approval as unverified. Sponsor submission announcement and September 2026 sponsor update.
What REDEFINE 1 found
REDEFINE 1 studied adults with overweight or obesity without diabetes. At 68 weeks, the paper reported a treatment-policy mean weight change of −20.4% with cagrilintide–semaglutide and −3.0% with placebo. Gastrointestinal events were common, mainly transient and mild to moderate. The study was funded by Novo Nordisk. REDEFINE 1 paper.
The submission announcement also emphasized an estimate assuming participants remained on treatment. Do not silently combine that figure with the paper’s treatment-policy result. They answer different questions about events such as stopping therapy. Read the definition, not just the heading used for the percentage.
REDEFINE 2 studied a different population
In adults with type 2 diabetes and overweight or obesity, REDEFINE 2 reported treatment-policy mean weight changes of −13.7% with the combination and −3.4% with placebo at 68 weeks. This is one reason diabetes status belongs beside a trial result. It is not appropriate to tell a person with diabetes to expect the average from a trial that excluded it. REDEFINE 2 paper.
A combined product is not a home combination protocol
Research on a defined fixed-dose combination does not establish that combining separately obtained products reproduces it. The tested formulation, manufacturing, dose schedule, and safety monitoring all matter. FDA has specifically raised concerns about unapproved GLP-1-related products and cagrilintide compounding. FDA safety information.
The trials also do not settle every comparison with currently approved treatments, long-term outcome, or population. A large average weight reduction is useful evidence, but it is not a reason to skip the safety and uncertainty sections.
What to watch next
A regulator-issued decision and approved product information would provide a different level of certainty about availability, indication, and use. Until that is verified, a responsible profile distinguishes development, application, and approval. Follow the original study and the regulator rather than a release date predicted by a seller or social-media post.
